Evidence map›Paper›PMID 35177127›Full record

ArticleNeurological research and practice2022

SOP: thrombolysis in ischemic stroke under oral anticoagulation therapy.

Pawel Kermer, Peter D Schellinger, Peter A Ringleb, Martin Köhrmann

Open access · diamondAbstract read
In one paragraph

Article in Neurological research and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Specific Reversal Agents for Direct Oral Anticoagulants in Acute Stroke.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Pawel KermerDepartment of Neurology, Friesland Kliniken gGmbH, Campus Nordwest-Krankenhaus Sanderbusch, Am Gut Sanderbusch 1, 26452, Sande, Germany. p.kermer@sanderbusch.de.ORCID http://orcid.org/0000-0001-5933-0985
Peter D SchellingerDepartment of Neurology and Neurogeriatrics, University Hospital, Johannes Wesling Klinikum/RU Bochum, Hans-Nolte-Straße 1, 32429, Minden, Germany.
Peter A RinglebDepartment of Neurology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Martin KöhrmannDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Heidelberg University · DEJohannes Wesling Klinikum Minden · DEKrankenhaus Nordwest · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBased on demographical trends and the expected worldwide increase in the number of individuals with atrial fibrillation, the rate of patients who are on oral anticoagulation therapy for secondary prevention of stroke rises continuously. Despite correct drug intake and good adherence to the respective medication, recurrent ischemic stroke still occurs in ~ 3% of patients. The question how to deal with such patients with regard to intravenous thrombolysis with rt-PA within the 4.5 h time window is of great relevance for daily clinical routine. However, international guidelines can be considered heterogenous or do even lack recommendations on this topic especially in light of available reversal agents. Therefore, we provide this SOP. COMMENTS: Beyond the identification of acute stroke patients on oral anticoagulation therapy, the type of medication, time since last intake, renal function and laboratory exams as well as the availability of reversal agents have to be considered before rt-PA application and potential endovascular therapy. Treatment on a Stroke Unit or Neuro-ICU is certainly recommended in any of those patients.

conclusionsThis standardized operating procedure was designed to guide stroke physicians through questions on eligibility for rt-PA treatment in patients with acute ischemic stroke who are on approved oral anticoagulation therapy thereby increasing the number of patients benefitting from thrombolysis and minimizing door-to-needle times.

Indexed as

Acute ischemic strokeAntidoteIv-thrombolysisOral anticoagulationRt-PA

Identifiers

PMID35177127
PMCPMC8851794
OpenAlexW4213144478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.